Member Exclusive News

The week in industry: the first oral drug for secondary progressive MS gets FDA approval

This week: Celgene and Exscientia enter partnership to accelerate drug discovery using artificial intelligence, Cardiff University launches new institute to develop new generation of therapeutics and AbbVie’s SKYRIZI™ gains its first approval in the Japanese market.

Go to the profile of RxNet
Mar 28, 2019

Please sign in or register for FREE

No comments yet.